SLC5A2 and type 2 diabetes mellitus: The present study was designed to evaluate blood glucose dynamics immediately after the start of SGLT2 inhibitor therapy (i.e., the immediate effect on blood glucose level), time of onset of action, and incidence of hypoglycemia in patients with T2DM admitted to our hospital.